

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/US04/018524

International filing date: 10 June 2004 (10.06.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/320,262  
Filing date: 12 June 2003 (12.06.2003)

Date of receipt at the International Bureau: 16 August 2004 (16.08.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1204566

UNITED STATES PATENT AND TRADEMARK OFFICE

TO ALL TO WHOM THESE SEEM PRESENTS: GENEVA, CONN.:


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

August 09, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/320,262  
FILING DATE: June 12, 2003  
RELATED PCT APPLICATION NUMBER: PCT/US04/18524

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office



**Electronic Filing System (EFS) Data  
Electronic Patent Application Submission  
USPTO Use Only**

EFS ID: 41786  
Application ID: 60320262   
Title of Invention: 2-difluoromethylphenyl-  
containing substrates for an  
analyte dependent enzyme  
activation system  
First Named Inventor: Mark Bobrow  
Domestic/Foreign Application: Domestic Application  
Filing Date: 2003-06-12  
Effective Receipt Date: 2003-06-12  
Submission Type: Provisional Application  
Filing Type: new-utility  
Confirmation number: 1407  
Attorney Docket Number: NONE  
  
Total Fees Authorized: 160.0  
Payment Category: Credit Card  
Credit Card Number: \*\*\*\*6836  
Expiration Date: 01312006  
Card Holder Name: Tom Mullinax  
Postal Code: 02118  
RAM Payment Status: RAM success  
RAM User ID: EFSPROD  
RAM Accounting Date: 2003-06-12  
RAM Sequence Number: 710386

Digital Certificate Holder: Not trusted entity.  
Certificate Message Digest: 1f8bec35b5d173fd2de56258df6141f92dcbf981

02499 USPS PRO  
60320262  
06/12/03



## TRANSMITTAL

Electronic Version v1.1  
Stylesheet Version v1.1.0

Title of Invention	2-difluoromethylphenyl-containing substrates for an analyte dependent enzyme activation system
Application Number:	
Date:	
First Named Applicant:	Dr. Mark Norman Bobrow
Confirmation Number:	
Attorney Docket Number:	

I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Submitted by:	Elec. Sign.	Sign. Capacity
Dr. Leslie Levine Registered Number: 35245	LL549-3	Attorney

Documents being submitted	Files
us-request	CARDP-usreq.xml us-request.dtd
us-fee-sheet	us-request.xsl CARDP-usfees.xml us-fee-sheet.xls
application-body	us-fee-sheet.dtd CARDAP1-trans.xml

us-application-body.xsl  
application-body.dtd  
wipo.ent  
mathml2.dtd  
mathml2-qname-1.mod  
isoamsa.ent  
isoamsb.ent  
isoamsc.ent  
isoamsn.ent  
isoamso.ent  
isoamsr.ent  
isogrk3.ent  
isomfrk.ent  
isomopf.ent  
isomscr.ent  
isotech.ent  
isobox.ent  
isocyr1.ent  
isocyr2.ent  
isodia.ent  
isolat1.ent  
isolat2.ent  
isonum.ent  
isopub.ent  
mmlextra.ent  
mmlalias.ent  
soextblk.dtd  
Fig1c.tif

Comments

**FEE TRANSMITTAL**

Electronic Version v08  
 Stylesheet Version v08.0

Title of Invention	2-difluoromethylphenyl-containing substrates for an analyte dependent enzyme activation system
Application Number:	
Date:	
First Named Applicant: Dr. Mark Norman Bobrow	
Attorney Docket Number:	

**TOTAL FEE AUTHORIZED \$160**

Patent fees are subject to annual revisions on or about October 1st of each year.

Filing as large entity

**BASIC FILING FEE**

Fee Description	Fee Code	Amount \$	Fee Paid \$
Provisional Filing Fee	1005	160	160
Subtotal For Basic Filing Fee: \$160			

**AUTHORIZED BILLING INFORMATION**

The commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Credit account number: 6836

Expiration Date (YYYYMMDD): 2006-01-31

Authorized name: Tom Mullinax

Billing address: 02118

## APPLICATION DATA SHEET

Electronic Version v14  
Stylesheet Version v14.0

## Title of Invention

2-difluoromethylphenyl-containing substrates for an analyte dependent enzyme activation system

Application Type: provisional, utility

## Correspondence address:

## Customer Number:

36761



## Inventor Information:

Inventor 1:

Applicant Authority Type: Inventor

Citizenship: US

Name prefix: Dr.

Given Name: Mark

Middle Name: Norman

Family Name: Bobrow

City of Residence: Lexington

State of Residence: MA

Country of Residence: US

Address-1 of Mailing Address: 11 Battle Green Rd.

Address-2 of Mailing Address:

City of Mailing Address: Lexington

State of Mailing Address: MA

Postal Code of Mailing Address:

Country of Mailing Address: US

Phone:

Fax:

E-mail:

Electronic Version

Stylesheet Version v1.1.1

## Description

# **2-difluoromethylphenyl-containing substrates for an analyte dependent enzyme activation system**

### **DETAILED DESCRIPTION**

[0001] Catalyzed reporter deposition (CARD) is a novel method of signal amplification which constitutes the subject matter of U.S. Pat. Nos. 5,731,158, 5,583,001 and 5,196,306. It is also discussed, and assays described in Bobrow et al., Journal of Immunological Methods, 125: 279-285 (1989) and in Bobrow et al., Journal of Immunological Methods, 137:103-112 (1991).

[0002] The CARD method utilizes an analyte-dependent enzyme activation system ("ADEAS") to catalyze the deposition of reporter or hapten groups (labels) onto a solid phase or proteins. These enzymatically deposited labels are detected directly or indirectly, resulting in signal amplification and improved detection limits. In the previously disclosed references, a peroxidase was the preferred enzyme.

[0003] The present invention involves methods and compounds for use with hydrolytic enzymes such as esterases, alkaline phosphatase and beta-galactosidase. These methods offer advantages over peroxidase based methods in that they are slower and more linear, allowing for greater

control and dynamic range.

[0004] As disclosed herein, the present invention relates to the use of 2-difluoromethylphenyl-containing compounds incorporated into hydrolase substrates. The term analyte dependent enzyme activation system (ADEAS) refers to an enzyme system wherein (i) at least one enzyme is coupled, in any manner known to those skilled in the art, to a member of a specific binding pair, or (ii) the enzyme need not be coupled to a member of a specific binding pair when it is the analyte. The enzyme, either by itself or in connection with a second enzyme, catalyzes the formation of a reactive intermediate which then is deposited wherever there is a receptor for the reactive intermediate.

[0005] The term surface as used herein means any solid support or phase known to those skilled in the art including, but not limited to cells, tissues, membranes, slides, beads and the surface of proteins.

[0006] The term amplification as used herein means amplification of reporter signal.

[0007] The term reactive intermediate means the 2-difluoromethylphenyl-containing compounds have been primed by the enzyme to bind to the receptor.

[0008] The term receptor means a site which will bind to the reactive intermediate through the formation of a covalent bond.

[0009]

The term detectably labeled means that the 2-difluoromethylphenyl-

containing compounds, in addition to the substrate characteristics, are coupled to a reporter or an unlabeled first member of a specific binding pair. In the case in which the compound is coupled to an unlabeled member of a specific binding pair, after the reactive intermediate is covalently bound to the receptor, the substrate-specific binding pair complex is reacted with the second member of the binding pair which is coupled to a reporter.

[0010] Members of specific binding pairs suitable for use in practicing the invention can be of the immune or non-immune type. Immune specific binding pairs are exemplified by antigen/antibody systems or hapten/anti-hapten systems such as dinitrophenyl (DNP)-anti-DNP. The antibody member, whether polyclonal, monoclonal or an immunoreactive fragment thereof, of the binding pair can be produced by customary methods familiar to those skilled in the art. The terms immunoreactive antibody fragment or immunoreactive fragment mean fragments which contain the binding region of the antibody. Such fragments may be Fab type fragments which are defined as fragments devoid of the Fc portion, e.g., Fab, Fab' and F(ab')<sub>2</sub> fragments, or may be so-called "half molecule" fragments obtained by reductive cleavage of the disulfide bonds connecting the heavy chain components of the intact antibody. If the antigen member of the specific binding pair is not immunogenic, e.g., a hapten, it can be covalently coupled to a carrier protein to render it immunogenic.

[0011]

Non-immune binding pairs include systems wherein the two

components share a natural affinity for each other but are not antibodies. Exemplary non-immune binding pairs are biotin-avidin or biotin-streptavidin, folic acid-folate binding protein, complementary probe nucleic acids, etc. Also included are non-immune binding pairs which form a covalent bond with each other. Exemplary covalent binding pairs include sulphydryl reactive groups such as maleimides haloacetyl derivatives and amine reactive groups such as isothiocyanates, succinimidyl esters, sulfonyl halides, and coupler dyes such as 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethyl-amino) benzoic acid (DMAB), etc.

[0012] The term deposition means directed binding of a reactive intermediate to the receptor which results from the formation of a covalent bond.


[0013] The enzyme catalyzes the deposition of a 2-difluoromethylphenyl-containing compound by converting the compound to a reactive intermediate which is capable of covalently binding to a receptor.

[0014] The present invention also concerns 2-difluoromethylphenyl-containing compounds which heretofore have not been described as enzyme substrates.

[0015] Enzymes suitable for use with 2-difluoromethylphenyl-containing compounds of the present invention include hydrolases. More particularly, phosphatases, glycosidases and esterases can be employed. One particularly preferred enzyme which is suitable for the novel substrates of the invention is alkaline phosphatase.

[0016] A wide variety of detectable labels are available for linking to the 2-difluoromethylphenyl-containing moiety, and the present invention is limited to any specific label. The detectable label can be a reporter as a radioactive isotope such as  $^{125}\text{I}$ , enzymes, fluorescent reagents or groups such as fluorescein, tetramethylrhodamine, cyanine dyes, Alexa dyes or BODIPY dyes, chemiluminescent reagents or groups, or electrochemical materials. The detectable label can also be a member of a specific binding pair as described above. Other labels will be readily apparent to one of skill in the art.

[0017] Compounds for use in assays of the present invention generally have the structure:



wherein Y is a moiety capable of being cleaved by a hydrolytic enzyme, L is a detectable label and X is a group linking L to the 2-difluoromethylphenyl moiety.


[0018] Moieties capable of being cleaved by hydrolytic enzymes include phosphate esters, glycoside esters such as galactose and glucose, and alkyl esters cleavable by non-specific esterases.

[0019]

The linker, X, group can be virtually any linker group capable of linking the detectable label to the 2-difluoromethylphenyl moiety, and the


invention is not limited to the use of any specific linkers. Any linear or branched alkyl (C<sub>1</sub> to C<sub>10</sub> for example) or aryl group can serve as a linker, the only requirement being that it links the 2-difluoromethylphenyl moiety with the label.

[0020] In another embodiment, novel compounds which are substrates for hydrolytic enzymes are disclosed. One example of such a compound is:



wherein Y is a group capable of being cleaved by a hydrolytic enzyme, L is a reporter and X is a group linking L to the 2-difluoromethylphenyl moiety.


[0021] A second example of a compound which is a substrate for hydrolytic enzymes is:



wherein Y is phosphate, L is a detectable label and X is a group linking L to the 2-difluoromethylphenyl moiety.

## Claims


- [c1] In an assay for detecting or quantitating an analyte, employing an analyte dependent enzyme activation system which reacts with a substrate portion of a conjugate which comprises a detectably labelled substrate for said enzyme, so as to form an activated conjugate, which activated conjugate covalently binds to a site on a surface having a receptor for said activated conjugate, said receptor not being reactive with the analyte dependent enzyme activation system, wherein the detectably labeled portion of the bound conjugate either directly or indirectly generates a signal which is detected or quantitated, the improvement comprising: using as said conjugate a 2-difluoromethylphenyl-containing compound having the structure:



wherein Y is a moiety capable of being cleaved by a hydrolytic enzyme, L is a detectable label and X is a group linking L to the 2-difluoromethylphenyl moiety.

- [c2] The assay according to claim 1, wherein Y is phosphate and L is a first member of a specific binding pair.


- [c3] The assay according to claim 2, wherein L is biotin or dinitrophenyl
- [c4] The assay according to claim 1, wherein Y is phosphate and L is a fluorescent group.
- [c5] The assay according to claim 4, wherein L is fluorescein, tetramethylrhodamine, sulforhodamine 101, a cyanine dye, Alexa dye or BODIPY dye.
- [c6] The assay according to claim 1, wherein Y is a glycoside and L is a first member of a specific binding pair.
- [c7] The assay according to claim 6, wherein L is biotin or dinitrophenyl
- [c8] The assay according to claim 1, wherein Y is a glycoside and L is a fluorescent group.
- [c9] The assay according to claim 8, wherein L is fluorescein, tetramethylrhodamine, sulforhodamine 101 a cyanine dye, Alexa dye or BODIPY dye.
- [c10] A 2-difluoromethylphenyl-containing compound having the structure:



wherein Y is a group capable of being cleaved by a hydrolytic enzyme, L is a reporter and X is a group linking L to the 2-difluoromethylphenyl moiety.


- [c11] A compound according to claim 10, wherein L is a fluorescent group.
- [c12] A compound according to claim 11, wherein L is fluorescein, tetramethylrhodamine, sulforhodamine 101, a cyanine dye, Alexa dye or BODIPY dye.
- [c13] A compound according to claim 10 wherein Y is phosphate.
- [c14] A compound according to claim 10 wherein Y is phosphate and L is a fluorescent group.
- [c15] A compound according to claim 14, wherein L is fluorescein, tetramethylrhodamine, sulforhodamine 101, a cyanine dye, Alexa dye or BODIPY dye.
- [c16] A compound according to claim 10 wherein Y is a glycoside.
- [c17] A compound according to claim 10 wherein Y is a glycoside and L is a fluorescent group.
- [c18] A compound according to claim 17 wherein L is fluorescein, tetramethylrhodamine, sulforhodamine 101, a cyanine dye, Alexa dye or BODIPY dye.
- [c19] A 2-difluoromethylphenyl-containing compound having the

structure:




wherein Y is phosphate, L is a first member of a specific binding pair and X is a group linking L to the 2-difluoromethylphenyl moiety.

- [c20] A compound according to claim 19, wherein L is biotin.
- [c21] A compound according to claim 19, wherein L is dinitrophenyl.
- [c22] A 2-difluoromethylphenyl-containing compound having the structure:



wherein Y is a glycoside, L is a first member of a specific binding pair other than biotin and X is a group linking L to the 2-difluoromethylphenyl moiety.

- [c23] A compound according to claim 22, wherein L is dinitrophenyl.
- [c24] A 2-difluoromethylphenyl-containing compound having the structure:



wherein  $\text{Y}$  is a glycoside other than galactose,  $\text{L}$  is a first member of a specific binding pair, and  $\text{X}$  is a group linking  $\text{L}$  to the 2-difluoromethylphenyl moiety.

# **2-difluoromethylphenyl-containing substrates for an analyte dependent enzyme activation system**

## **Abstract**

This invention relates to 2-difluoromethylphenyl-containing compounds and the use of 2-difluoromethylphenyl-containing compounds as hydrolytic enzyme substrates in a variety of applications such as catalyzed reporter deposition